NEW YORK (GenomeWeb) – Canadian biopharmaceutical firm BiOasis last week announced that it has thrown its hat into the RNAi therapeutics ring and aims to advance an siRNA-based drug into Phase I testing before the end of next year.

While BiOasis hasn't made a final decision on what will be its first RNAi candidate, the firm recently presented limited data showing that its delivery technology could successfully carry siRNAs targeting Nox4, a gene involved in the generation of reactive oxygen species, across the blood-brain barrier (BBB).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.